Novartis AG

Lichtstrasse 35
Basel

Switzerland

Phone: (877) 999-8850
Fax: (212) 830-2405
Email: investor.relations@group.novartis.com
Web Site: http://www.novartis.com/

A. Company Profile

Novartis (NYSE:NVS) is one of the world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology. Novartis is a world leader in the generation of cancer drugs.

B. Products

Product Pipelines

1. Femara

Femara (Letrozole) is an aromatase inhibitor and a highly potent estrogen suppressor in postmenopausal women with advanced breast cancer. It acts by interfering with the production of estrogen triggered by aromatase and reduces the total amount of estrogen in the body. As a result, less estrogen can reach breast cancer cells.Hormone-dependent breast cancers contain protein molecules called estrogen receptors. When no estrogen is present, the estrogen receptors remain inactive. When the estrogen receptors are exposed to estrogen, however, they trigger a chain of events that results in tumor cell growth and multiplication. Aromatase enzyme is needed to convert androgen into estrogen, which results in tumor growth. Femara binds to the aromatase enzyme and blocks it from converting androgen to estrogen, thereby reducing growth of the tumor. Tumors that contain these estrogen receptors are known as estrogen receptor-positive (ER+) tumors. These are the cancers that can be treated by Femara (and other hormonal therapies), to deprive them of estrogen.

2. Gleevec

Gleevec (Imatinib mesylate) is believed to work by interfering with the abnormal protein and blocking it from telling the body to keep making more and more abnormal white blood cells. It is a therapy that affects the molecular cause of chronic myelonic leukemia. In chronic myelonic leukemia, there is a constant signal that tells the body to keep producing abnormal white blood cells. The constant signal is created by three events: first, there is a change in a person's DNA; second, this change forms the Philadelphia (Ph) chromosome (named after the city where it was discovered), third, the Ph chromosome creates an abnormal protein that tells the body to send out the constant signal.

3. RAD001

RAD is an oral inhibitor of mTOR

4.Sandostatin LARDepot

Sandostatin LARDepot is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and is also indicated for long-term treatment of the profuse watery diarrhea associated with Vasoactive Intestinal Peptide Tumors (VIPomas).

4. Zometa

Zometa (zoledronic acid) is indicated for the treatment of hypercalcemia of malignancy. Zometa is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Bone metastases, the spread of cancerous cells from the primary tumor to the bones, are a frequent and debilitating complication of many cancers. Among the most common cancers to spread to the bone are: prostate cancer, breast cancer, lung cancer, and multiple myeloma (cancer that begins in the bone marrow).

5. PKC 412

PKC412 is a kinase inhibitor that blocks several isoforms of protein kinase C (PKC) and receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor, and stem cell factor, inhibits vascularization.

6. PTK787

PTK787, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor,may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.